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Thalidomide is reported to have therapeutic utility in more than 2-fold in the colloidal gold assay and more
than 3-fold in the scratch assay over control. Althoughthe treatment of pyoderma gangrenosum, Behc¸et’s
disease, aphthous ulcers, and skin wounds. We investi- pro-migratory, thalidomide did not alter the level of
metalloproteinase-9 secreted into culture medium.gated the effect of thalidomide on human keratinocyte
proliferation and migration, two early and critical Thalidomide did, however, induce a 2–4-fold increase
in keratinocyte-derived interleukin-8, a pro-migratoryevents in the re-epithelialization of skin wounds. Tha-
lidomide at concentrations less than 1 mM did not affect cellular autocrine factor. Human keratinocyte migra-
tion and proliferation are essential for re-epithelializ-keratinocyte viability. Using a thymidine incorporation
assay, we found that thalidomide, at therapeutic con- ation of skin wounds. Interleukin-8 increases human
keratinocyte migration and proliferation and is chemo-centrations, induced more than a 2.5-fold increase in
the proliferative potential of the cells. Keratinocyte tactic for keratinocytes. Therefore, thalidomide may
modulate keratinocyte proliferation and motility by amigration was assessed by two independent motility
assays: a colloidal gold assay and an in vitro scratch chemokine-dependent pathway. Key words: cytokine/re-
epithelialization/wound healing. J Invest Dermatol 113:720–assay. At optimal concentrations, thalidomide
increased keratinocyte migration on a collagen matrix 724, 1999
T by demonstrating that it inhibited basic fibroblast growth factor-induced corneal neovascularization in rabbits (D’Amato et al, 1994).The effect of thalidomide on leukocytes has been extensivelyinvestigated in vitro; however, there are no studies in the literatureregarding its effect on keratinocytes (Neubert et al, 1996). Thalidom-
ide has been demonstrated to be of therapeutic benefit in a variety
halidomide [(N)-phthalimidoglutarimide] is a syn-
thetic derivative of glutamic acid. It was widely
prescribed in the late 1950s as a sedative-hypnotic,
but was withdrawn from the market in the early
1960s because it was found to be a potent teratogen
(Ochonisky and Revuz, 1994; Tseng et al, 1996). Sheskin (1965,
of mucocutaneous disorders including aphthous ulceration, Behc¸et’s1980) fortuitously found that it was extremely effective in the
disease, and pyoderma gangrenosum (Rustin et al, 1990; Gardner-treatment of erythema nodosum leprosum. Subsequently, several
Medwin et al, 1994b; Jacobson et al, 1997; Hecker and Lebwohl,other dermatoses have also been reported to be responsive to
1998). It has been assumed that the beneficial effect of thalidomidethalidomide. Consequently, there has been a growing interest in
upon these conditions is due to the drug’s anti-inflammatorythis drug, whose mechanism of action is not yet fully known or
properties as it reduces polymorphonuclear leukocyte chemotaxisunderstood (Grosshans and Illy, 1984; Naafs and Faber, 1985;
and phagocytosis, and also inhibits soluble inflammatory mediatorsGardner-Medwin and Powell, 1994a).
such as prostaglandins (Nasca et al, 1999). Another commonThalidomide has anti-angiogenic, anti-inflammatory, and immu-
denominator to many conditions in which thalidomide has anomodulating properties. It inhibits leukocyte chemotaxis and
therapeutic benefit, however, appears to be ulcerative skin wounds.phagocytosis, lysosome degranulation, and mast cell activation
Because, the healing of cutaneous ulceration requires re-epithelializ-(Barnhill et al, 1984). It also induces a decrease in the T helper/T
ation, we wondered if one of the beneficial effects of thalidomidesuppressor ratio of T cells (Gad et al, 1985; Moncada et al, 1985;
might be directly upon keratinocyte motility and proliferation, twoShannon et al, 1992; Nogueira et al, 1994). The immunologic
early and critical events in resurfacing skin wounds. A few hourseffects of thalidomide may depend on the inhibition of tumor
after wounding, keratinocytes migrate laterally over the woundnecrosis factor-α (Sampaio et al, 1991; Moreira et al, 1993), and
bed. Approximately 1 d later, the cells at the edge of the epitheliumupon the downregulation of several cell surface adhesion markers
begin to proliferate and contribute cells to the advancing tongueon blood leukocytes (Neubert et al, 1992, 1993; Nogueira et al,
of migrating keratinocytes involved in resurfacing the wound1994). The anti-angiogenic effect of thalidomide was confirmed
(Odland and Ross, 1968; Woodley et al, 1993). We therefore
hypothesized that thalidomide might increase keratinocyte migra-
tion and/or proliferation, as these are two fundamental steps in re-
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In this study, we used two independent in vitro migration assaysReprint requests to: Dr. David T. Woodley, Division of Dermatology,
to examine the effects of thalidomide on human keratinocyteUniversity of Southern California, Ambulatory Health Center, 1355 San
migration on type I collagen, a matrix molecule found in thePablo Street, Los Angeles, CA 90033, U.S.A.
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MATERIALS AND METHODS experimental condition. Each experiment was repeated three times and
the counts were averaged.
Materials Rat-tail collagen I was obtained from Collaborative Biochem-
icals. Trypan blue 0.4% was obtained from Sigma (St Louis, MO). Safety Gelatin zymography Keratinocytes were plated on tissue-culture plastic
Solve was obtained from Research Products International (Mount Prospect, at a density of 20,000 cells per cm2. After the cells attached, unattached
IL). Tritiated thymidine was obtained from ICN Biomedicals. Thalidomide cells were aspirated and thalidomide was added at various concentrations
(a racemic mixture of D[1] and L[–] forms was supplied by Pediatric (0.001–100 nM). Media were harvested after 12 h, centrifuged at 4°C
Pharmaceuticals Incorporated (Westfield, NJ). Thalidomide was initially (1500 3 g) for 10 min to remove cells and debris, and concentrated 5-fold
solubilized in dimethylsulfoxide and further dilutions were made in with a Centricon 30 (Amicon, Beverly, MA). The effect of thalidomide
keratinocyte serum-free medium. Mitomycin-C was obtained from Sigma. on metalloproteinase-9 (MMP-9) secreted into the media was evaluated
by gelatin-ladened zymography as previously described (Sarret et al, 1992a).
Cell culture Human keratinocytes obtained from neonatal foreskins Triplicate experiments were performed.
were cultured in low calcium (0.09 mM), serum-free MCDB 153 medium
(Gibco BRL, Gaithersburg, MD) as described by Boyce and Ham (1983), Interleukin (IL)-8 protein determination Human keratinocytes were
and modified by O’Keefe and Chiu (1988). All experiments were performed cultured in basal medium prior to trypsinization, then plated on tissue
using human keratinocytes between second and fourth passages. Ker- culture plastic at a concentration of 15,000 cells per cm2. After the cells
atinocytes from 10 donor foreskins were used in this study. At least three attached, increasing concentrations of thalidomide were added to the dishes
different donor foreskins were used in each experiment. (0.001–100 nM), and the cells were incubated for 12 h. The concentration
of IL-8 in the conditioned medium was then measured using a commercially
Cell viability available enzyme-linked immunosorbent assay (Quantikine; R&D Systems,
Lactate dehydrogenase cytotoxicity assay To quantitate the cellular toxicity of Minneapolis, MN) able to detect 4.7 pg IL-8 per ml. Standard curves for
thalidomide, we used a commercially available Cytotoxicity Detection Kit recombinant human IL-8 ranging up to 2000 pg per ml were run for each
from Boehringer-Mannheim. This is a colorimetric assay which measures assay. Protein levels in the supernatants were normalized to total cell
the lactate dehydrogenase activity released from damaged cells. Ker- number. Each supernatant was analyzed in triplicate. This experiment was
atinocytes were plated in 24 well plates (5000 cells per well), allowed to repeated three times.
attach and then treated with increasing concentrations of thalidomide for
16 h. The medium was harvested and the assay was performed as described RESULTS
(Racher et al, 1990). Percentage cytotoxicity was calculated from the
Concentrations of thalidomide , 1 mM do not affect ker-mean of triplicate absorbance values using a formula incorporating the
atinocyte viability Keratinocyte viability after exposure to tha-experimental value, low control and high control.
lidomide was examined by calculating the percentage of nonviable
Cell migration assays cells using an lactate dehydrogenase release cytotoxicity assay. As
Colloidal gold assay The method of Albrecht-Buehler (1977), as modified shown in Fig 1, increasing cytotoxicity was observed with increas-
by Woodley et al (1988), was used to evaluate keratinocyte motility. ing concentrations of the drug, whereas concentrations , 1 µM
Coverslips were coated with colloidal gold salts, washed, and type I collagen minimally affected cell viability. Because keratinocyte cytotoxicity(8 µg per ml) in Hanks’ balanced salt solution supplemented with calcium
was observed at concentrations of thalidomide . 1 µM (Fig 1),and magnesium was added to each well. Dishes were incubated at 37°C
we used thalidomide at concentrations between 0.001 and 100 nMfor 2 h to permit immobilization of collagen to the coverslips. Passage 3
for all biologic assays in this study.keratinocytes were plated in each well at a density of 750 cells per cm2.
After attachment, media containing various concentrations of thalidomide
Thalidomide increases keratinocyte migrationwere added to each well (0.001–100 nM). Triplicate wells were used for
in vitro Human keratinocytes were exposed to a substratum ofeach experimental condition. Cultures were incubated at 37°C, 5% CO2
type I collagen (8 µg per ml). The keratinocytes are maximallyfor 16 h, washed and fixed in 0.1% formaldehyde in phosphate-buffered
stimulated to migrate on a type I collagen matrix of 15 µg per mlsaline. Because the doubling time of keratinocytes under these conditions
is approximately 30 h, the assay assesses cellular motility unconfounded by or greater. This optimal matrix provides migration indices above
cell division. To quantitate migration, cells were examined with an Olympus
inverted microscope under dark-field optics and the percentage of each
field occupied by migration tracks, a so-called migration index, was
calculated using computer-assisted image analysis (Chen et al, 1993). The
images of 10 fields per condition were analyzed.
In vitro scratch assay A second migration assay, the so-called ‘‘scratch assay’’
was performed according to Cha et al (1996). Keratinocytes (40,000 per
cm2) were plated in tissue culture dishes, and after 24 h of incubation, the
cells were incubated with 10 µg per ml of mitomycin-C for 2 h to inhibit
cell proliferation, and the confluent monolayer of cells was scratched in a
standardized manner with a plastic apparatus to create a cell-free zone in
each well, 2 mm in width. The medium was aspirated and replaced with
keratinocyte medium with or without the presence of thalidomide (0.001–
100 nM). The cells were then incubated for 24 h at 37°C. In vitro re-
epithelialization was documented by photography, and the amount of
migration was quantitated by computer-assisted image analysis using NIH
Image 1.6. The residual gap between the migrating keratinocytes was
measured and expressed as a percentage of the area of the scratch remaining
unfilled. Each experiment was performed in triplicate.
Thymidine incorporation assay The proliferative potential of human
keratinocyte cultures with and without the presence of thalidomide was
determined by the thymidine incorporation assay of O’Keefe and Chiu
(1988). Keratinocytes were plated in 24 well dishes (20,000 cells per cm2)
and allowed to attach. Cells were then exposed to thalidomide diluted in Figure 1. Concentrations of thalidomide , 1 mM do not affect
keratinocyte viability. Keratinocytes were plated in 12 well plates,keratinocyte medium (0.001–100 nM) for 12 h and 2 µCi of (3H)thymidine
(New England Nuclear Products, Boston, MA) were added per well. Cells allowed to attach and treated with increasing concentrations of thalidomide.
The medium was harvested and the amount of lactate dehydrogenasewere incubated at 37°C for 8 h. Medium was aspirated and the cells were
washed three times with ice-cold phosphate-buffered saline, twice with released into the medium calculated as described in the Materials and
Methods. Data are expressed as the mean 6 SD of triplicate values fromice-cold trichloracetic acid and solubilized with 0.1 M NaOH containing
1% sodium dodecyl sulfate. Solubilized radioactivity was counted in a three experiments. *p , 0.05 compared with no added thalidomide.
**p , 0.001 compared with no added thalidomide.scintillation counter with Safety Solve. Ten wells were used for each
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30. Therefore, the 8 µg per ml collagen matrix used in these Thalidomide does not alter keratinocyte gelatinase
secretion Many factors that promote keratinocyte motility alsoexperiments is a ‘‘suboptimal’’ matrix that provides migration indices
increase MMP-9 activity, for example, hypoxia, collagen I, andof approximately 20. As shown in Fig 2, the presence of thalidomide
cyclic adenosine monophosphate (Iwasaki et al, 1994; Sarret et al,at 0.01 nM, 0.1 nM, and 1 nM increased the migration indices
1992a; O’Toole et al, 1997). MMP-9 is also known as type IVfrom 20.2 6 1.1 to 22.25 6 1.1 and 27.45 6 1.3, respectively.
collagenase/gelatinase and has a molecular weight of 92 kDa. UsingTriplicate independent experiments were performed. Thalidomide
standard gelatin zymography, we examined the expression ofeffect on keratinocyte motility with suboptimal amounts of collagen
MMP-9 in keratinocytes cultured with and without nontoxicwas statistically significant (p , 0.05), when analyzed by the
concentrations of thalidomide. Increasing concentrations of thalid-Student’s t test. On an ‘‘optimal’’ matrix of 15 µg per ml of
omide did not alter keratinocyte expression of MMP-9 (datacollagen, keratinocytes migrated maximally and no thalidomide
not shown).enhancement in cellular motility could be detected (data not shown).
To confirm the results of the colloidal gold assay, we assessed
Thalidomide increases keratinocyte IL-8 production IL-8motility in the scratch assay with and without thalidomide. In the
serves as a keratinocyte autocrine factor and is a cytokine thatscratch assay, keratinocytes were plated densely in tissue culture
promotes keratinocyte motility. We wished to determine if thewells for 24 h incubated with mitomycin-C to inhibit proliferation,
thalidomide-induced enhancement of keratinocyte motility wasthen a standardized scratch was made through the confluent
associated with an altered expression of keratinocyte-derived IL-8.monolayer, as previously described (Cha et al, 1996). Keratinocytes
IL-8 production in the supernatant of keratinocytes with andfrom the cut edge of the scratch were then allowed to migrate for without thalidomide was measured by enzyme-linked immunosorb-12 h in the presence of increasing amounts of thalidomide and ent assay. Cell counts were performed to ensure that an approxi-photographed. The residual scratch area between inwardly migrating mately equal number of cells attached for each condition. IL-keratinocytes from the edges of the scratch was measured as 8 protein activity was detected in unconcentrated conditioneddescribed in Materials and Methods. As shown in Fig 3, the keratinocyte medium. As shown in Fig 5, the presence of thalidom-
keratinocytes migrated inwardly and covered a greater area of the ide increased IL-8 secretion in a concentration-dependent manner.
scratch in the presence of thalidomide (compare 3B with 3G), Untreated keratinocytes, secreted basal levels of IL-8 (4.2 6 0.2 pg
when compared with assays without thalidomide (3A). As shown per ml). In the presence of 0.1 nM, 1 nM, and 10 nM of
in the bar graph (Fig 3), keratinocytes on plastic exposed to thalidomide, the keratinocytes secreted 9.2 6 0.9 pg IL-8 per ml,
thalidomide at concentrations of 0.001 nM, 0.01 nM, 0.1 nM, 11.5 6 0.8 pg IL-8 per ml, and 16.3 6 1 pg IL-8 per ml,
1 nM, 10 nM, and 100 nM, migrated to fill 42 6 3.9, 52 6 4.8, respectively.
61 6 5.9, 70 6 7.2, 82 6 7 and 90 6 9.2% of the scratch area,
respectively. Concentrations greater than 0.1 nM significantly DISCUSSION
promoted keratinocyte migration (p , 0.05, Student’s t test).
In recent years, thalidomide has been used successfully in the
treatment of several dermatoses characterized by loss of tissue,Thalidomide increases keratinocyte proliferation in vitro In
including aphthous stomatitis, genital aphthosis, Behc¸et’s diseaseorder to determine if thalidomide affects the growth potential
(Grinspan et al, 1989; Revuz et al, 1990; Revuz, 1990; Gardner-of keratinocyte cultures, the ability of human keratinocytes to
Medwin et al, 1994b), aphthous ulcers in AIDS patients (Patersonincorporate tritiated thymidine in the presence of noncytotoxic
et al, 1995; Jacobson et al, 1997), and pyoderma gangrenosumdoses of thalidomide was assessed according to O’Keefe and Chiu
(Munro and Cox, 1988; Rustin et al, 1990). Thalidomide has a(1988). As shown in Fig 4, human keratinocytes cultured in serum-
number of side-effects but most of these are relatively uncommon.free medium in the presence of 0.01–100 nM of thalidomide had
Two of the most serious side-effects are peripheral neuropathy,increased levels of thymidine incorporation compared with those
which is not uncommon and often dose-related, and its very highwithout thalidomide. This effect was concentration-dependent up
incidence of teratogenicity in the event of fetal exposure.to a concentration of 0.1 nM. At concentrations . 0.1 nM,
To insure that the effects of thalidomide upon keratinocytethalidomide increased keratinocyte proliferation, but not as signi-
migration and proliferation were not due to nonspecific toxicityficantly as with lower concentrations.
of the drug, we determined the range at which thalidomide
could be used without causing nonspecific toxicity using a lactate
dehydrogenase cytotoxicity assay. The noncytotoxic concentrations
of thalidomide used in the proliferation and motility assays were
well within the therapeutically effective plasma levels of thalidomide
used in human diseases (Chen et al, 1989; Boughton et al, 1995).
The mode of action of thalidomide is unclear, but thalidomide is
a potent immunomodulatory and anti-inflammatory agent (Paterson
et al, 1995) that selectively reduces tumor necrosis factor-α expres-
sion (Sampaio et al, 1991). Tumor necrosis factor-α promotes
neutrophil maturation and keratinocyte IL-8 secretion, which
enhances neutrophil chemotaxis (Moreira et al, 1993; Costa et al,
1994). Neutrophils at the wound site destroy contaminating bacteria
(Tannesh et al, 1988), but this may cause further damage to healing
tissue. Keratinocyte migration and proliferation are fundamentally
important steps in re-epithelializing skin wounds (Woodley et al,
1993). In this study, thalidomide not only promoted keratinocyte
motility in two independent migration assays, but also increased
the cell’s proliferative potential. Thus, thalidomide may influence
two fundamental mechanisms involved in wound healing. In this
study, low concentrations of thalidomide produced a marked
Figure 2. Thalidomide promotes keratinocyte migration in the increase in keratinocyte proliferation; however, higher concentra-colloidal gold assay. Keratinocytes were allowed to migrate for 16 h, in
tions were required to increase keratinocyte migration significantly.the presence of increasing concentrations of thalidomide. Ten migration
This may be because keratinocyte migration requires new proteinindices were calculated for each condition and the experiment was repeated
synthesis, redistribution of lamellipodia-associated proteins, andthree times. Error bars; mean 6 SD. *p , 0.004 compared with no added
thalidomide. synthesis and secretion of collagenases (O’Toole et al, 1997). These
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Figure 3. Thalidomide promotes keratinocyte migration in the in vitro scratch assay. An in vitro wound was introduced in confluent cultures of
normal human keratinocytes, as described in the Materials and Methods. The cells were incubated without thalidomide (A) or with increasing concentrations
of thalidomide (B–G). After 24 h, the cells were photographed under phase-contrast microscopy. Scale bar: 250 µm. The percentage of the original scratch
area remaining unfilled was calculated by image analysis and expressed as the mean 6 SD of three observations (graph). 10–12–10–7 5 0.001–100 nM.
Figure 5. Thalidomide increases human keratinocyte IL-8
Figure 4. Thalidomide promotes keratinocyte proliferation in vitro. secretion. Keratinocytes cultured in basal medium were plated on plastic
Subconfluent keratinocytes in 24 well plates were exposed to increasing at a concentration of 15,000 cells per cm2. After cell attachment, increasing
concentrations of thalidomide for 12 h, then incubated with 2 µCi of concentrations of thalidomide were added to the dishes. After 12 h,
thymidine for an additional 8 h. Cellular samples were prepared as described the concentration of IL-8 was measured in unconcentrated conditioned
in the Materials and Methods and the amount of solubilized radioactivity medium. Error bars, mean 6 SD of three experiments performed in
was counted in a scintillation counter. Error bars, mean 6 SD of three triplicate. *p , 0.001 compared with control without thalidomide.
experiments performed in triplicate. **p , 0.0005 compared with control
**p , 0.0005 compared with control without thalidomide.
without thalidomide. *p , 0.001 compared with control without
thalidomide.
IL-8 is known to enhance human keratinocyte chemotaxis
(Schro¨der, 1992) and proliferation (Tuschil et al, 1992) and to beprocesses may require higher doses of thalidomide compared with
DNA synthesis. increased in diseases characterized by epidermal hyperproliferation,
such as psoriasis (Nickoloff et al, 1991, 1994). In this study, lowMatrix-induced promotion of keratinocyte motility is associated
with increased synthesis of collagenases (Petersen et al, 1987, 1989; concentrations of thalidomide (0.01–0.1 nM) promoted human
keratinocyte proliferation, whereas higher concentrations also pro-Sarret et al, 1992a; Iwasaki et al, 1994). Degradation of matrix
allows for detachment of keratinocyte-matrix adhesions, and this moted human keratinocyte proliferation, but not as markedly as
the lower concentrations. These data are in accordance withprocess allows the cell to continue to migrate during re-epithelializ-
ation. Our study demonstrates that thalidomide does not alter the other studies of other cell types showing opposite biologic effects
depending upon the concentration of thalidomide used (McHughexpression of keratinocyte-derived MMP-9, a collagenase linked
to keratinocyte migration on a collagen matrix (Sarret et al, 1992a). et al, 1995). IL-8 secretion, evaluated by enzyme-linked immuno-
sorbent assay, showed a 2–4-fold increase compared with controlTherefore, the enhancement of human keratinocyte motility by
thalidomide likely involves some other mechanism. human keratinocytes in the presence of thalidomide. Therefore,
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Ewan PW: The immunosuppressive drug thalidomide induces T-helper cell typethe thalidomide-induced enhancement of keratinocyte motility
2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- andmay be mediated via an increased expression of IL-8 which would antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp
act as a pro-migratory autocrine factor. Immunol 99:160–167, 1995
Moncada B, Baranda ML, Gonzalez-Amaro R, Urbina R, Loredo CE: ThalidomideKeratinocyte migration and proliferation are independent mech-
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independent mechanisms (Chen et al, 1993). In this study, we Neubert R, Nogueira AC, Neubert D: Thalidomide derivatives and the immune
system. I. Changes in the pattern of integrin receptors and other surface markersfind that thalidomide enhances both keratinocyte migration and
on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 67:1–17, 1993proliferation in vitro. The therapeutic value of thalidomide in the
Neubert R, Hinz N, Thiel R, Neubert D: Down-regulation of adhesion receptors ontreatment of chronic wounds has yet to be determined. The positive cells of primate embryos as a probable mechanism of the teratogenic action of
effect of thalidomide on both migration and proliferation in vitro, thalidomide. Life Sci 58:295–316, 1996
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